Replies to post #392734 on NorthWest Biotherapeutics Inc (NWBO)

[Dr Bala]

Analysis of the blinded interim data on OS of the ITT population (using SAS version 9.4) was performed 34 months after the midpoint of patient enrollment, and 16 months after the last patient was enrolled and randomized.

Ref.: Liau et al. J Transl Med (2018) 16:142

[flipper44]

They said they were going to do one in 2014, and instead they resized the trial and increased event requirements. She said they were going to do one in 2015, but instead were caught off guard by screening pause, recommendations not to unblind and SAP modification. You like to give credit for LP heading toward ruin, longs like to give her credit for steering the ship through rough waters. In hindsight, I think LP is a pragmatic, reasoned leader that had the reigns taken from her in order that a new field of cancer treatment is appropriately presented. Don’t get me wrong. I think she balances many complex goals, but I think regulators and researchers are getting this right, yet often putting LP and others in awkward positions. You are a bulldog with your teeth gripped into the wrong agenda. I neither like nor hate LG and LP, because I don’t have enough info to form an opinion. What I do know is the science is developing rapidly, and if you didn’t understand what Dr. Pazdur said about modifying definitions and therapeutic targeting, then you missed the forest. There is no question LP will come out smelling like a rose financially, but I think you’ve let her business acumen/greed distort the bigger picture, which is the birth of a platform to increase therapeutic efficacy against an otherwise intractable disease.

[biosectinvestor]

They did not and this has been conclusively shown by me time and time again. You all go away when I do it. And then come back months later with the same argument.